JTI's Revenue and Profit Hits Record High in 2022

Feb.15.2023
JTI's Revenue and Profit Hits Record High in 2022
Japan Tobacco's 2022 earnings report shows 14.3% YoY revenue growth and record high profits from increased sales of heated tobacco products.

On February 14th, Japan Tobacco Inc. (JTI) released their financial report for the year 2022. According to the report, JTI saw a 14.3% increase in revenue, with earnings of ¥26,578 billion ($201 billion) compared to the previous year. Net profit also rose by 30.8% to ¥4,427 billion ($33.4 billion), marking a new record for both revenue and net profit.


JTI's 2022 financial report, as shown in the accompanying image.


The market share of heated tobacco sticks continues to grow as sales of Ploom X double.


JTI's heat-not-burn tobacco device, Ploom X, launched in August 2021, has doubled its sales in 2022 compared to the previous year. As a result of Ploom X's success, JTI's revenue related to the device increased by 18.7%, and their adjusted operating profit increased by 31.7%.


The market share of heat-not-burn tobacco products (HTS) has reached 7.7%, showing a 20% increase compared to the same period last year. As a result of the growth in HTS products, the reduced-risk product (RRP) category has also increased by 9.2%.


Overall, thanks to the robust performance of MEVIUS, Camel, and Ploom X, JTI's total tobacco sales and market share have both increased.


Furthermore, in major markets such as Italy, the Philippines, Spain, Taiwan, and Turkey, JTI has seen an increase in market share.


The President and CEO of JTI, Masamichi Terabatake, has announced that 2022 marks the first year of JTI's tobacco business structure integration. During this year, JTI has taken various measures to strengthen their business capabilities. With the growth of Ploom X, JTI anticipates further positive developments in the future, particularly in the heated tobacco stick (HTS) sector, which will support their ambition to achieve a balanced revenue stream in the Reduced Risk Product (RRP) category by 2028.


Revenue from two major business segments decreases, tobacco business generates $17.18 billion in revenue.


JTI's tobacco business revenue increased by 15.6% to 2,315.2 billion yen ($17.36 billion), while its adjusted operating profit rose by 18% to 754 billion yen ($5.65 billion) year-on-year. The increase was mainly attributed to higher investment in Ploom X and rising input costs within the supply chain.


Tobacco Business Report | Image Source: JTI


The pharmaceutical business of JTI recorded a revenue of JPY 82.9 billion (USD 620 million), which marks a 3.1% year-on-year increase. The adjusted operating profit was JPY 11.1 billion (USD 83 million), reflecting a marginal growth of 0.5% from the previous year. The increase is mainly attributed to the revenue growth of its subsidiary, Torigoe Pharmaceutical.


The processed food business of JTI has recorded a revenue of 155.5 billion yen ($1.166 billion), marking a 5.6% YoY increase. The adjusted operating profit is reported to be 3.5 billion yen ($0.26 billion), down by 11.3% YoY. The decline in revenue is attributed to the share transfer of bakery stores, while the price adjustments in frozen and ambient food business are the key reasons behind the rising profits.


It is predicted that revenue will decrease by 1.1% in 2023, prompting a significant increase in investment in heated tobacco products.


JTI predicts that its revenue will decrease by 1.1% to 2.629 trillion yen ($19.87 billion) in 2023. Its operating profit is expected to decline by 6.4% to 612 billion yen, and the net profit attributable to the owners of the parent company is anticipated to decrease by 0.6% to 440 billion yen.


According to Masamichi Terabatake, JTI must heavily invest in HTS by 2023 in order to lay the foundation for future revenue growth.


JTI plans to steadily increase its DPS in accordance with its shareholder return policy. The goal of this policy is to achieve a 75% dividend payout ratio through sustainable growth in medium to long-term profits.


Reference:


2022 Financial Results Announcement


For further reading:


Japan Tobacco's revenue in 2022 reaches a new historical high, and the company plans to invest heavily in heated pods in 2023.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

South Korean Parliament advances revision of tobacco law to include synthetic nicotine products, expected to generate $6.3 billion in tax revenue
South Korean Parliament advances revision of tobacco law to include synthetic nicotine products, expected to generate $6.3 billion in tax revenue
South Korean Parliament advances tobacco law revision, including synthetic nicotine products, anticipating $630 million tax revenue increase.
Oct.16 by 2FIRSTS.ai
Eagle, Colorado Passes Ban on Flavored Tobacco; New Rules Set to Take Effect January 1, 2026
Eagle, Colorado Passes Ban on Flavored Tobacco; New Rules Set to Take Effect January 1, 2026
The town council of Eagle, Colorado, has voted to approve an ordinance restricting the sale of flavored tobacco products, aiming to reduce youth exposure to and use of nicotine. Supporters argue that flavors entice minors to start, and that a ban will help lower usage rates; opponents worry about impacts on retailers and tax revenue. Thirteen other cities in the state have already adopted similar policies, and nearly 400 municipalities and six states nationwide have imposed restrictions. Eagle’s
Sep.03 by 2FIRSTS.ai
France Bans Oral Nicotine Products in Forms of Pouches, Pastes, Tablets, and Liquids Starting March 2026
France Bans Oral Nicotine Products in Forms of Pouches, Pastes, Tablets, and Liquids Starting March 2026
France's Decree No. 2025-898 bans all oral nicotine products nationwide six months after publication. Medicines and medical devices are exempt. This includes nicotine pouches, gum, lozenges, and other forms, regardless of origin. The decree is based on the Public Health Code and applies to mainland France and Wallis and Futuna Islands.
Sep.08
Products | "Pod Mod Surge" Accelerates Post-Disposable Ban as VOZOL Launches New Pod System in the UK
Products | "Pod Mod Surge" Accelerates Post-Disposable Ban as VOZOL Launches New Pod System in the UK
After the disposable vape ban took effect, updates to the pod category in the UK's MHRA database surged, showing that the market is rapidly pivoting to reusable pod systems. Against this backdrop, 2FIRSTS observed that VOZOL also recently launched a new pod product in the UK, which this article will examine in detail.
Aug.28 by 2FIRSTS.ai
UK MHRA Approved E-cigarette Products List Updated | 46 SKUs Approved, INNOKIN Submits New Products Across Multiple Categories(9.1 - 9.7)
UK MHRA Approved E-cigarette Products List Updated | 46 SKUs Approved, INNOKIN Submits New Products Across Multiple Categories(9.1 - 9.7)
The Medicines and Healthcare products Regulatory Agency (MHRA) database was updated with 46 e-cigarette SKUs from September 1-7, with Shenzhen INNOKIN Technology Co., Ltd. (INNOKIN) being the most active, having multiple new devices and pods approved. Meanwhile, although the number of updates has decreased, pre-filled pods remain the most approved category this week.
Sep.08
Although not yet approved by the FDA, Altria still plans to launch its new nicotine pouch product, on! PLUS™, in the U.S
Although not yet approved by the FDA, Altria still plans to launch its new nicotine pouch product, on! PLUS™, in the U.S
Altria announced that its subsidiary, Helix, will launch a new nicotine pouch product, on! PLUS™, in the U.S. this fall, with the initial markets covering North Carolina, Texas, and Florida. The product has not yet been approved by the FDA. It is noteworthy that the launch time and regions for on! PLUS™ are highly similar to those of BAT's planned disposable e-cigarette, Vuse One.
Aug.25